Literature DB >> 21879295

Animal tumor models for PET in drug development.

Jun Toyohara1, Kiichi Ishiwata.   

Abstract

Positron emission tomography (PET) is being increasingly applied to animal tumor models due to the need for proof-of-concept testing and preclinical efficacy studies of anticancer agents. Regardless of the nature of an experiment, investigators should carefully select a suitable animal tumor model as part of the experimental design. This review introduces sources of information and the guiding principles regarding applicability of various animal tumor models for PET in anticancer agent development especially for small animals.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21879295     DOI: 10.1007/s12149-011-0531-x

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  4 in total

1.  Evaluation of the Genisys4, a bench-top preclinical PET scanner.

Authors:  Ken Herrmann; Magnus Dahlbom; David Nathanson; Liu Wei; Caius Radu; Arion Chatziioannou; Johannes Czernin
Journal:  J Nucl Med       Date:  2013-04-29       Impact factor: 10.057

2.  Dynamical observation on biological progression of VX2 liver tumors to identify the optimal time for intervention in animal models.

Authors:  Zhenguang Wang; Guangjie Yang; Pei Nie; Junhua Fu; Xufu Wang; Dan Liu
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

3.  Monitoring metabolic responses to chemotherapy in single cells and tumors using nanostructure-initiator mass spectrometry (NIMS) imaging.

Authors:  Peter J O'Brien; Michelle Lee; Mary E Spilker; Cathy C Zhang; Zhengming Yan; Timothy C Nichols; Wenlin Li; Caroline H Johnson; Gary J Patti; Gary Siuzdak
Journal:  Cancer Metab       Date:  2013-01-23

4.  Neuroprotective effect of the traditional Chinese herbal formula Tongxinluo: a PET imaging study in rats.

Authors:  Xiao Cheng; Haoxuan Luo; Lihua Zhou; Lixin Wang; Jingbo Sun; Yan Huang; Enli Luo; Yefeng Cai
Journal:  Neural Regen Res       Date:  2014-07-01       Impact factor: 5.135

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.